

Contact:

Jeff Misakian, Valeant Pharmaceuticals
949-461-6184

**VALEANT PHARMACEUTICALS LAUNCHES DERMATIX™ ULTRA ADVANCED
SCAR TREATMENT IN THE UNITED STATES**

ALISO VIEJO, Calif., October 1, 2007 - Valeant Pharmaceuticals International (NYSE: VRX) today announced that it has launched Dermatix™ Ultra Advanced Scar Treatment for the prevention and reduction of hypertrophic and keloid scars. Dermatix Ultra is a transparent, fast-drying silicone gel with unique qualities, making it ideally suited to help minimize or reduce signs and symptoms of abnormal scarring and aid in the prevention and reduction of hypertrophic scarring after surgery. This new formulation is available through dermatologists, plastic surgeons and online health and beauty retailers without a prescription.

Dermatix Ultra has been shown to flatten, soften and smooth scars, relieving itching and discomfort. The new proprietary silicone technology imparts a soft silky feel to the skin, without oily residue or buildup and can be used under makeup and clothing making it ideally suited for use after laser and surgical cosmetic procedures.

“This is an exciting addition to our dermatology portfolio of products,” said Wesley P. Wheeler, president, North America and Research and Development. “We believe the scientifically supported benefits of Dermatix Ultra, along with its technologically advanced smooth formulation will position the brand as the proven therapy of choice by physicians and their patients.”

The number of people worldwide who develop a scar annually is estimated to be 100 million with 31 percent reporting the scar as a reminder of a traumatic experience.² Scar prevention has been documented as an important consideration with many patients experiencing psychological distress because of scars.³ Physicians have found it simpler to prevent abnormal scarring through appropriate management of surgical and trauma wounds than to treat established hypertrophic and keloid scars.⁴

About Valeant:

Valeant Pharmaceuticals International (NYSE: VRX) is a global specialty pharmaceutical company that develops, manufactures and markets products primarily in the areas of neurology, infectious disease and dermatology. More information about Valeant can be found at www.valeant.com.

Dermatix Ultra Advanced Scar Treatment is a trademark of Valeant Pharmaceuticals International or its related companies. For information on Dermatix Ultra Advanced Scar Treatment visit www.DermatixUltra.com.

1. Mustoe, TA, Equivalent Efficacy of Silicone Gel (Dermatix™ Ultra) and Silicon Gel Sheeting in Scar Management: Clinical Results and Mechanism of Action. Poster accepted at the 2007 21st World Congress of Dermatology, Oct. 1-5, 2007,
2. Bayat and al. , Skin scarring, BMJ 2003 ; 326 : 88 –92.
3. Devlin-Rooney K, James W. Management and prevention of abnormal scars. Nus Stand 2005; 19:45-54; quiz 55-56.
4. Spellman J. Topical Dermatix® gel for the management of scars; a pilot study. Presented at the SCAR 2006 Annual Meeting, April 27-30, 2006, Austin TX.